Increasing Access to Genetic Testing in Underserved Patients Using a Multilingual Conversational Agent

使用多语言会话代理增加服务不足的患者获得基因检测的机会

基本信息

  • 批准号:
    10624338
  • 负责人:
  • 金额:
    $ 78.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-06-01 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT Background. The volume of patients who meet national criteria for germline genetic testing based on a cancer diagnosis alone, regardless of family history (i.e. ovarian, pancreatic, advanced prostate, etc.) is rapidly growing. Germline genetic test results can inform oncology and surgical treatment decisions, as well as early detection and prevention for the family. However, traditional pre- and post-test genetic counseling approaches may not be sufficient to meet the growing need. Additionally, traditional pre-test counseling may be a barrier, leading to decreased uptake, especially in those with advanced disease. Patients cared for in settings with limited or no genetic services, including low-literacy, non-English speaking, and rural community patients already face disparities in access. As such, these patients remain underrepresented in clinical and research cohorts, and innovative strategies to optimize genetic counseling approaches are understudied. Relational Agents (RAs) are an effective means of automating health education and counseling, as well as overcoming literacy barriers in the use of information technologies. RAs, animated computer characters simulate face-to-face conversation between a patient and a provider using verbal and nonverbal conversational behavior. Overall Goals. This study will develop an English and Spanish RA to communicate personalized pre-test genetic education to a cohort of cancer patients who meet established cancer-based genetic testing criteria across two diverse clinical settings (including a low-resource, urban, safety-net hospital and a university medical center that serves a significant rural population). We hypothesize that the use of an RA will increase the proportion of patients who receive genetic test results within 90 days of initiating cancer care, compared to usual care. Aim 1 is to develop an English- and Spanish-language RA using a patient-driven approach. Aim 2 is to conduct a multisite randomized controlled trial of the RA to deliver pre-test education versus usual care in English- and Spanish-speaking patients to compare the proportion in each arm who receive genetic test results in 90 days at Los Angeles County+University of Southern California Medical Center and University of Rochester Medical Center. Aim 3 is to understand the implementation context and identify facilitators and barriers to utilizing the RA in these clinical settings. Impact. Our deliverable will be multilingual patient-facing RA to deliver pre-test genetic education. This RA will be developed and evaluated in two distinct patient populations and clinic workflows, can be rapidly updated as practice evolves, and will ultimately be available on the internet for clinics and patients to utilize. If successful, this would be a novel, effective, and scalable means of providing genetics education that could improve patient decisional preparedness, knowledge, and satisfaction, ultimately leading to increased access for patient populations who are traditionally underserved in genetics. Understanding the implementation context and identifying facilitators and barriers to integrating a RA will increase sustainability and generalizability.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TIMOTHY W. BICKMORE其他文献

TIMOTHY W. BICKMORE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TIMOTHY W. BICKMORE', 18)}}的其他基金

Advancing Medical Illustration in Patient Education Materials: from Art to Science
推进患者教育材料中的医学插图:从艺术到科学
  • 批准号:
    10660634
  • 财政年份:
    2023
  • 资助金额:
    $ 78.25万
  • 项目类别:
Sustaining recovery for people on opioid agonist treatment with conversational agents
使用对话代理维持阿片类激动剂治疗患者的康复
  • 批准号:
    10810952
  • 财政年份:
    2023
  • 资助金额:
    $ 78.25万
  • 项目类别:
Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care
会话代理可提高初级保健中 HPV 疫苗的接受度
  • 批准号:
    10665764
  • 财政年份:
    2022
  • 资助金额:
    $ 78.25万
  • 项目类别:
Improving PRO Interpretation at the Individual Level for Patients with Cancer using Conversational Agents and Data Visualization
使用对话代理和数据可视化改善癌症患者个体水平的 PRO 解释
  • 批准号:
    10807160
  • 财政年份:
    2022
  • 资助金额:
    $ 78.25万
  • 项目类别:
Increasing Access to Genetic Testing in Underserved Patients Using a Multilingual Conversational Agent
使用多语言会话代理增加服务不足的患者获得基因检测的机会
  • 批准号:
    10444758
  • 财政年份:
    2022
  • 资助金额:
    $ 78.25万
  • 项目类别:
Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care
会话代理可提高初级保健中 HPV 疫苗的接受度
  • 批准号:
    10757090
  • 财政年份:
    2022
  • 资助金额:
    $ 78.25万
  • 项目类别:
Community-based Design and Evaluation of a Conversational Agent to Promote SARS-COV2 Vaccination in Black Churches
基于社区的对话代理的设计和评估,以促进黑人教堂中的 SARS-COV2 疫苗接种
  • 批准号:
    10345674
  • 财政年份:
    2021
  • 资助金额:
    $ 78.25万
  • 项目类别:
Community-based Design and Evaluation of a Conversational Agent to Promote SARS-COV2 Vaccination in Black Churches
基于社区的对话代理的设计和评估,以促进黑人教堂中的 SARS-COV2 疫苗接种
  • 批准号:
    10543531
  • 财政年份:
    2021
  • 资助金额:
    $ 78.25万
  • 项目类别:
Community-based Design and Evaluation of a Conversational Agent to Promote SARS-COV2 Vaccination in Black Churches
基于社区的对话代理的设计和评估,以促进黑人教堂中的 SARS-COV2 疫苗接种
  • 批准号:
    10397175
  • 财政年份:
    2021
  • 资助金额:
    $ 78.25万
  • 项目类别:
Conversational Agents to Improve Quality of Life in Palliative Care
对话代理可提高姑息治疗中的生活质量
  • 批准号:
    10117443
  • 财政年份:
    2016
  • 资助金额:
    $ 78.25万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 78.25万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 78.25万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 78.25万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 78.25万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 78.25万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 78.25万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 78.25万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 78.25万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 78.25万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 78.25万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了